Inherited metabolic diseases and pregnancy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 112, Issue 1, 2005, Pages 2-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARYLBUTYRIC ACID DERIVATIVE; BENZOIC ACID; BETAINE; CITRULLINE; CYANOCOBALAMIN; FOLIC ACID; NITROGEN; PENICILLAMINE; PYRIDOXINE; SODIUM PHENYLBUTYRATE; TYROSINE; UNCLASSIFIED DRUG; ZINC;

ACIDEMIA; AMINO ACID METABOLISM; BRAIN DISEASE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIET RESTRICTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EMBRYO DEVELOPMENT; ENTERIC FEEDING; FATTY ACID OXIDATION; FETUS DISEASE; HUMAN; INBORN ERROR OF METABOLISM; INFORMATION RETRIEVAL; INHERITANCE; MATERNAL DISEASE; MEDLINE; METABOLIC DISORDER; PHENYLKETONURIA; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; RISK ASSESSMENT; UREA CYCLE; VITAMIN SUPPLEMENTATION;

FEMALE; FETAL DISEASES; HUMANS; METABOLISM, INBORN ERRORS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 11844257625     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00297.x     Document Type: Review

References (100)

1. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;47:105 (e10).
2. Walter JH. Inborn errors of metabolism and pregnancy. J Inherit Metab Dis 2000;23:229-236.
3. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999;20:519-529.
4. Wong W, Eskes TKAB, Kuijpers-Jagtman AM, et al. Nonsyndromic orofacial clefts: association with maternal hyperhomocysteinemia. Teratology 1999;60:253-257.
5. Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland homocystein study. Am J Clin Nutr 2000;71:962-968.
6. Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996;93:15227-15232.
7. Schimanski U, Krieger D, Horn M, Stremmel W, Wermuth B, Theilmann L. A novel two-nucleotide deletion in the ornithine transcarbamylase gene causing fatal hyperammonia in early pregnancy. Hepatology 1996;24:1413-1415.
8. Wong L-JC, Craigen WJ, O'Brien WE. Postpartum coma and death due to carbamoyl-phosphate synthetase I deficiency. Ann Intern Med 1994;120:216-217.
9. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. N Engl J Med 1990;322:1652-1655.
10. Lenke RL, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 1980;303:1202-1208.
11. Levy HL, Guldberg P, Güttler F, et al. Congenital heart disease from the maternal PKU collaborative study. Pediatr Res 2001;49:636-642.
12. Drogari E, Smith I, Beasly M, Lloyd JK. Timing of strict diet in relation to fetal damage in maternal PKU study. Lancet 1987;ii:927-930.
13. Cipcic-Schmidt S, Trefz FK, Fünders-Bücker B, Seidlitz G, Ullrich K. German maternal phenylketonuria study. Eur J Pediatr 1996;155(Suppl 1):S173-S176.
14. Koch R, Friedman E, Azen C, et al. The international collaborative study of maternal phenylketonuria. Eur J Pediatr 2000;159(Suppl 2):S156-S160.
15. Anonymous. Recommendations on the dietary management of phenylketonuria. Arch Dis Child 1993;68:426-427.
16. Trefz FK. Blood phenylalanine control in the maternal PKU study-influence of dietary control on offspring outcome in early treated women with PKU. J Inherit Metab Dis 2002;25:621.
17. Rohr FJ, Lobbregt D, Levy HL. Tyrosine supplementation in the treatment of maternal phenylketonuria. Am J Clin Nutr 1998;67:473-476.
18. van Spronsen FJ, van Rijn M, Bekhof J, Koch R, Smit GPA. Phenylketonuria: tyrosine supplementation in the phenylalanine restricted diet. Am J Clin Nutr 2001;73:153-157.
19. Verkerk PH, van Spronsen FJ, Smit GPA, Cornel MC, Kuipers JRG, Verloove-Vanhorick SP. Prevalence of congenital heart disease in phenylketonuric patients. J Pediatr 1991;119:282-283.
20. Verkerk PH, van Spronsen FJ, Smit GPA, Sengers RCA, on behalf of the National PKU Steering Committee. Impaired prenatal and postnatal growth in Dutch patients with phenylketonuria. Arch Dis Child 1994;71:114-118.
21. Crockett DJ, Woolf LI, McBean MS, Woolf FM, Cahalane SF. Birth weight and pathogenesis in phenylketonuria. Int J Neurosci 1990;54:259-266.
22. Cerone R, Fantasia AR, Castellano E, Moresco L, Schiaffino MC, Gatti R. Pregnancy and tyrosinaemia type II. J Inherit Metab Dis 2002;25:317-318.
23. Francis DEM, Kirby DM, Thompson GN. Maternal tyrosinemia II: management and successful outcome. Eur J Pediatr 1992;151:196-199.
24. Takayama N, Hamada H, Kubo T. Lysinuric protein intolerance in pregnancy: case report with successful outcome. Arch Gynecol Obstet 1995;256:49-52.
25. Shih VE, Aubry RH, DeGrande G, Gursky SF, Tanaka K. Maternal isovaleric acidemia. J Pediatr 1984;105:77-78.
26. van Calcar SC, Harding CO, Davidson SR, Barness LA, Wolff JA. Case reports of successful pregnancy in women with maple syrup urine disease and propionic acidemia. Am J Med Genet 1992;44:641-646.
27. Diss E, Jams J, Reed N, Roe DS, Roe C. Methylmalonic aciduria in pregnancy. A case report. Am Obstet Gynecol 1995;172:1057-1059.
28. Grünewald S, Hinrichs F, Wendel U. Pregnancy in woman with maple syrup urine disease. J Inherit Metab Dis 1998;21:89-94.
29. Evans MI, Duquette DA, Rinaldo P, et al. Modulation of B12 dosage and response in fetal treatment of methylmalonic aciduria (MMA): titration of treatment dose to serum and urine MMA. Fetal Diagn Ther 1997;12:21-23.
30. Van Rijn M, Huitema S, Rake JP, et al. Dietary management of glycogen storage disease 1a patients in pregnancy. J Inherit Metab Dis 2000;23(Suppl 1):162.
31. Fernandes J, Smit GPA. Glycogen storage diseases. In: Fernandes J, Saudubray JM, van den Berghe G, editors. Inborn Metabolic Diseases. Diagnosis and Treatment, 3rd edition. Heidelberg: Springer, 2000: 87-101.
32. Gitzelmann R. Disorders of galactose metabolism. In: Fernandes J, Saudubray JM, van den Berghe G, editors. Inborn Metabolic Diseases. Diagnosis and Treatment, 3rd edition. Heidelberg: Springer, 2000: 103-109.
33. Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 1990;13:802-818.
34. Blake LL, Sha R. Mitochondrial myopathy in a primagravid pregnancy. Br J Obstet Gynaecol 1999;106:871-873.
35. Yanagawa T, Sakaguchi H, Nakao T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with deterioration during pregnancy. Intern Med 1998;37:780-783.
36. Berkowitz K, Monteagudo A, Marks F, Jackson U, Baxi L. Mitochondrial myopathy and preeclampsia associated with pregnancy. Am J Obstet Gynecol 1990;162:146-147.
37. Dreval D, Bernstein D, Zakut H. Carnitine palmitoyl transferase deficiency in pregnancy: a case report. Am J Obstet Gynecol 1994;170:1390-1392.
38. Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol 1996;91:2293-2300.
39. Shekahawat P, Bennet MJ, Sadovsky Y, Nelson DM, Rakheja D, Strauss AW. Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab 2003;284:E1098-E1105.
40. Kaushansky A, Frydman M, Kaufman R. Endocrine studies of the ovulatory disturbances in Wilson's disease. Fertil Steril 1987;47:270-273.
41. Schagen van Leeuwen JH, Christiaens GCML, Hoogenraad TU. Recurrent abortion and the diagnosis of Wilson disease. Obstet Gynecol 1991;78:547-549.
42. Fasouliotis SJ, Ezra Y, Schenker JG. Gaucher's disease and pregnancy. Am J Perinatol 1998;15:311-318.
43. Torloni MR, Franco K, Sass N. Gaucher's disease with myocardial involvement in pregnancy. Sau Paulo Med J/Rev Paul Med 2002;120:90-92.
44. De Koning TJ, Jaeken J, Pineda M, Van Maldergem L, Poll-The BT, van der Knaap MS. Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 2000;31:287-292.
45. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelly RI. Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet 1997;68:263-269.
46. Volpe JJ, Adams RD. Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathol 1972;20:175-198.
47. Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993;91:915-921.
48. Derry JMJ, Gormally E, Means GD, et al. Mutations in a deltha 8 deltha 7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctata. Nat Genet 1999;22:286-290.
49. Paupe A, Bidat L, Sonigo P, Lenclen R, Molho M, Ville Y. Prenatal diagnosis of hypoplasia of the corpus callosum in association with non-ketotic hyperglycinemia. Ultrasound Obstet Gynecol 2002;20:616-619.
50. deMeirler L, Lissens W, Denis R, et al. Pyruvate dehydrogenase deficiency; clinical and biochemical diagnosis. Pediatr Neurol 1993;9:216-220.
51. North KN, Hoppel CL, De Girolami U, Kozakewich HPW, Korson MS. Lethal neonatal deficiency of carnitine palmitoyltransferase II associated with dysgenesis of the brain and kidneys. J Pediatr 1995;127:414-420.
52. Elpeleg ON, Hammerman C, Saada A, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 2001;102:183-187.
53. Brown GK, Hunt SM, Scholem R, et al. Betha-hydroxyisobutyryl coenzyme A deacylase deficiency: a defect in valine metabolism associated with physical malformations. Pediatrics 1982;70:532-538.
54. de Koning TJ, de Vries LS, Groendendaal F, et al. Pontocerebellar hypoplasia associated with respiratory chain defects. Neuropaediatrics 1999;30:93-95.
55. Lincke CR, van den Bogert C, Nijtmans LG, Wanders RJA, Tamminga P, Barth PG. Cerebellar hypoplasia in respiratory chain dysfunction. Neuropediatrics 1996;27:216-218.
56. Aynaci FM, Mocan H, Bahadir S, Sari A, Aksoy A. A case of Menkes syndrome associated with deafness and inferior cerebellum vermian hypoplasia. Acta Paediatr 1997;86:121-123.
57. Holzbach U, Hanefeld F, Helms G, Hänicke W, Frahm J. Localized proton magnetic resonance spectroscopy of cerebral abnormalities in children with carbohydrate-deficient glycoprotein syndrome. Acta Paediatr 1995;84:781-786.
58. Bamforth FJ, Bamforth JS, Appelgarth DA. Structural anomalies in patients with inherited metabolic diseases. J Inherit Metab Dis 1994;17:330-332.
59. Nissenkorn A, Michelson M, Ben-Zeev B, Lerman-Sagie T. Inborn errors of metabolism. A cause of abnormal brain development. Neurology 2001;56:1265-1272.
60. Robinson BH, MacMillan H, Petrova-Benedict R. Variable clinical presentation in patients with defective E1 component of pyruvate dehydrogenase complex. J Pediatr 1987;11:525-533.
61. Samson JF, Barth PG, de Vries JIP, et al. Familial mitochondrial encephalopathy with fetal ultrasonographic ventriculomegaly and intracerebral calcifications. Eur J Pediatr 1994;153:510-516.
62. Kerrigan JF, Aleck KA, Tarby TJ, Bird CR, Heidenreich RA. Fumaric aciduria: clinical and imaging features. Ann Neurol 2000;47:583-588.
63. Shevell MI, Didomenicantonio G, Sylvain M, Arnold DL, O'Gorman AM, Scriver CR. Glutaric acidemia type II: neuroimaging and spectroscopy evidence for developmental encephalomyopathy. Pediatr Neurol 1994;12:350-353.
64. Chitayat D, Meagher-Villemure K, Mamer OA, et al. Brain dysgenesis and congenital intracerebral calcification associated with 3-hydroxyisobutyric aciduria. J Pediatr 1992;121:86-89.
65. Pannier E, Viot G, Aubrey MC, et al. Congenital erythropoietic porphyria (Günther's disease): two cases with very early prenatal manifestation and cystic hygroma. Prenat Diagn 2003;23:25-30.
66. Jaeken JC, Freson K, Goemans NM, et al. G protein diseases: newly recognized causes of metabolic encephalopathy. EPJN 2003;7:211-215.
67. Lin SK, Hsu SG, Ho ESC, et al. Novel mutation and prenatal sonographic findings of glutaric aciduria (type 1) in two Taiwanese families. Prenat Diagn 2002;22:725-729.
68. Daikha-Dahmane F, Dommergues M, Narcy F, et al. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. Pediatr Dev Pathol 2001;4:180-184.
69. Steenhout P, Elmer C, Clercx A, et al. Carnitine deficiency with cardiomyopathy presenting as neonatal hydrops: successful response to carnitine therapy. J Inherit Metab Dis 1990;13:69-75.
70. Wraith JE. Lysosomal disorders. Semin Neonatol 2002;7:75-83.
71. Bonduelle M, Lissens W, Goossens A, et al. Lysosomal storage diseases presenting as transient or persistent hydrops fetalis. Genet Couns 1991;2:227-232.
72. Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr 1999;46:409-440.
73. De Koning TJ, Toet M, Dorland L, et al. Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis 1998;21:681-682.
74. Cox PM, Brueton LA, Murphy KW, et al. Early-onset fetal hydrops and muscle degeneration in siblings due to a novel variant of type IV glycogenosis. Am J Med Genet 1999;86:187-193.
75. Linck LM, Hayflick SJ, Lin DS, et al. Fetal demise with Smit-Lemli-Opitz syndrome confirmed by tissue sterol analysis and the absence of measurable 7-dehydrocholesterol deltha-7-reductase activity in chorionic villi. Prenat Diagn 2000;20:238-240.
76. Maymon R, Ogle RF, Chitty LS. Smith-Lemli-Opitz syndrome presenting with persisting nuchal oedema and non-immune hydrops. Prenat Diagn 1999;19:105-107.
77. Benardis PG, Ikomi AA, Bateman SG, Bowyer JJ. An inborn error of metabolism imitating hypoxic-ischaemic encephalopathy. Br J Obstet Gynaecol 2000;107:941-942.
78. Wapner RJ, Lewis D. Genetic and metabolic causes of stillbirth. Semin Perinatol 2002;26:70-74.
79. Taroni F, Gellera C, Cavadini P, et al. Lethal carnitine palmitoyltransferase (CPT) II deficiency in newborn: a molecular-genetic study. Am J Hum Genet 1994;55:A245.
80. Schoeman MN, Batey RG, Wilcken B. Recurrent acute fatty liver pregnancy associated with a fatty-acid oxidation defect in the offspring. Gastroenterology 1991;100:544-548.
81. Wilcken B, Leung K-C, Hammond J, Kamath R, Leonard JV. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993;341:407-408.
82. Isaacs JD, Sims HF, Powell CK, et al. Maternal acute fatty liver of pregnancy associated with fetal trifunctional protein deficiency: molecular characterization of a novel maternal mutant allele. Pediatr Res 1996;40:393-398.
83. Tiny T, Ekholm E, Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol 1998;178:603-608.
84. Strauss AW, Bennet MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-coA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol 1999;23:100-112.
85. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999;340:1723-1731.
86. Innes AM, Sergeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000;47:43-45.
87. Chakrapani A, Olpin S, Cleary M, Walter JH, Wriath JE, Besley GTN. Trifunctional protein deficiency: three families with significant maternal hepatic dysfunction in pregnancy not associated with E474Q mutation. J Inherit Metab Dis 2000;23:826-834.
88. den Boer MEJ, Ijlst L, Wijburg FA, et al. Heterozygosity for the common LCHAD mutation (1528G > C) is not a major cause of HELLP syndrome and the prevalence of the mutation in the Dutch population is low. Pediatr Res 2000;48:151-154.
89. Tein I. Metabolic disease in the fetus predisposes to maternal hepatic complications of pregnancy. Pediatr Res 2000;47:6-8.
90. Nelson J, Lewis B, Walters B. The HELLP syndrome associated with fetal medium chain acyl-CoA dehydrogenase deficiency. J Inherit Metab 2000;23:518-519.
91. Rakheja D, Bennett MJ, Foster BM, Domiati-Saad R, Rogers BB. Evidence for fatty acid oxidation in human placenta, and the relationship of fatty acid oxidation enzyme activities with gestational age. Placenta 2002;23:447-450.
92. Ijlst L, Ruiter JPN, Hoovers JMN, Jakobs ME, Wanders RJA. Common missense G1528C in long-chain 3-hydroxyacyl-coA dehydrogenase deficiency. J Clin Invest 1996;98:1028-1033.
93. den Boer MEJ. Mitochondrial trifunctional protein in disease and development. Thesis, Amsterdam. December 2003.
94. van der Molen EF, Verbruggen B, Novakova I, Eskes TKAB, Monnens LAH, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br J Obstet Gynaecol 2000;107:785-791.
95. Diagnosis and management of fetal death. ACOG Technical Bulletin Number 176, January 1993. Int J Gynaecol Obstet 1993;42:291-299.
96. Early pregnancy loss. ACOG Technical Bulletin. Number 212, September 1995.
97. Royal College of Obstetrics and Gynaecologists. Clinical Green Top Guidelines: The Management of Recurrent Miscarriage. Available: http://www.rcog.org.uk/guidelines/recurrent.html.
98. De Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg BME, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997;104:1428-1454.
99. Brookes JCA, Hall-Craggs MA, Sams VR, Lees WR. Non-invasive perinatal necropsy by magnetic resonance imaging. Lancet 1996;348:1139-1141.
100. Royal College of Obstetrics and Gynaecologists. Clinical Green Top Guidelines: Management of Eclampsia. Available: http://www.rcog.org.uk/ guidelines/eclampsia.html.